10-Q: Polomar Health Services Completes Reverse Merger, Reports Q3 Results

Polomar Health Services, formerly Trustfeed Corp., completed a reverse merger with Polomar Specialty Pharmacy and reported its financial results for the quarter ended September 30, 2024.

Summary

• Polomar Health Services, previously known as Trustfeed Corp., finalized a reverse merger with Polomar Specialty Pharmacy on September 30, 2024.
• The merger resulted in Polomar Specialty Pharmacy becoming a wholly-owned subsidiary of Polomar Health Services.
• The company's Q3 2024 revenue was $9,849, and $37,954 for the nine months ended September 30, 2024, compared to $21,457 and $24,556 for the same periods in 2023.
• Operating expenses increased to $268,037 for the three months ended September 30, 2024, and $632,217 for the nine months ended September 30, 2024.
• The company reported a net loss of $271,333 for the three months ended September 30, 2024, and $622,544 for the nine months ended September 30, 2024.
• As of September 30, 2024, the company had $16,202 in cash and a working capital deficit of $797,658.
• The company has a going concern warning due to its history of losses and negative cash flows.
• The company is planning to launch PoloMeds and expand its prescription fulfillment services.
• The company acquired SlimRx, a weight loss platform, as part of the merger.
• The company is licensed to dispense compounded medications in 28 states and is seeking further approvals.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning, substantial losses, and a working capital deficit. While there are positive developments such as the merger and new business initiatives, the overall financial picture is concerning.

Positives

• The company completed a reverse merger, which is a significant strategic move.
• The company is now operating a licensed specialty pharmacy with the ability to dispense medications in 28 states.
• The company has acquired SlimRx, a weight loss platform, which provides a potential revenue stream.
• The company is planning to launch PoloMeds, which will expand its product offerings.
• The company is actively seeking approvals to expand its dispensing capabilities to more states.

Negatives

• The company has a history of losses and negative cash flows.
• The company has a significant working capital deficit of $797,658.
• The company has a going concern warning, indicating substantial doubt about its ability to continue operations.
• The company's revenue for the three and nine months ended September 30, 2024, was lower than the same periods in 2023.
• Operating expenses have increased significantly compared to the previous year.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate revenues and raise capital.
• The company has not generated sufficient revenues to finance its operations internally.
• The company faces risks related to obtaining adequate financing on a timely basis.
• The company faces risks related to its operations and uncertainties related to its business plan and strategy.
• The company faces competition in the pharmaceutical and telehealth industries.
• The company faces cybersecurity concerns.
• The company is subject to legislative and regulatory changes concerning platforms with data about companies.

Future Outlook

The company anticipates launching PoloMeds in the fourth quarter of 2024, expanding its prescription fulfillment services, and seeking approvals to operate in more states. The company also anticipates applying for a drug export permit in early 2025. The company expects steady growth in its wholesale business over the next 12 to 18 months.

Management Comments

• Management believes that all adjustments considered necessary for a fair presentation have been included.
• Management plans to raise additional capital and invest in its newly acquired business and other potential opportunities.
• Management is currently in the process of looking for additional investors.

Industry Context

The company's move into the specialty pharmacy and telehealth space aligns with the growing trend of online healthcare services and the increasing demand for compounded medications. The acquisition of SlimRx and the planned launch of PoloMeds position the company to capitalize on these trends. The company is competing with other online pharmacies and telehealth providers.

Comparison to Industry Standards

• The company's revenue is significantly lower than established players in the pharmaceutical and telehealth industries.
• The company's operating expenses are high relative to its revenue, indicating a need for improved efficiency.
• The company's net loss is substantial, highlighting the challenges of achieving profitability in the early stages of operation.
• The company's working capital deficit is a concern, suggesting a need for additional funding.
• The company's going concern warning is a significant risk factor that is not typical for established companies in the industry.
• Comparible companies include those in the online pharmacy and telehealth space such as Amazon Pharmacy, Capsule, and Teladoc Health, which have significantly higher revenues and more established operations.

Management Changes

Corporate Governance

Related Party Transactions

• The company borrowed $821,425 from a related party for operating expenses during the nine months ended September 30, 2024.
• Reprise Management, Inc., an affiliate of CWR, issued an unsecured promissory note to Polomar for up to $700,000.
• Trustfeed entered into a Promissory Note and Loan Agreement with CWR for up to $250,000.
• Affiliates of CWR owned a majority of the membership interests of Polomar immediately prior to the merger.
• Pinata Holdings, Inc., an affiliate of CWR, licensed intellectual property to the company.

Stakeholder Impact

• Shareholders experienced a change in ownership structure due to the reverse merger.
• Employees are impacted by the change in company focus and potential restructuring.
• Customers of Polomar Specialty Pharmacy and SlimRx are now served by the merged entity.
• Suppliers and creditors are affected by the company's financial condition and ability to meet its obligations.

Next Steps

• The company plans to launch PoloMeds in the fourth quarter of 2024.
• The company plans to expand its prescription fulfillment services.
• The company plans to seek approvals to operate in more states.
• The company anticipates applying for a drug export permit in early 2025.
• The company plans to raise additional capital.

Key Dates

Keywords

reverse merger, specialty pharmacy, compounding pharmacy, telehealth, prescription fulfillment, pharmaceutical, weight loss, SlimRx, PoloMeds, financial results, going concern, intellectual property